Sanity Group
Unlocking the potential of cannabinoids to develop innovative pharmaceuticals and consumer health products.
Unlocking the potential of cannabinoids to develop innovative pharmaceuticals and consumer health products.
Sanity Group is a Berlin based company pioneering the use of cannabinoids for medicinal and health purposes. Their operations cover medicinal cannabis, consumer health, and technology. The company is committed to developing and distributing innovative cannabinoid-based pharmaceuticals and wellness products across Europe. The company has received a €2.50M investment from OrganiGram in the secondary market on 25 June 2024, indicating a strong vote of confidence from the market. With a focus on biotechnology, health care, and health and wellness, Sanity Group presents an opportunity for investors to tap into the promising potential of cannabinoids. They are also seeking partnerships with cultivation facilities globally to expand their European footprint. This company's dedication to unlocking the potential of cannabinoids makes it a compelling player in the rapidly growing market.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Secondary Market | €2.50M | 1 | OrganiGram | 25 Jun 2024 |
| Convertible Note | €11.50M | 1 | OrganiGram | 25 Jun 2024 |
| Series B | $37.60M | 3 |
|
26 Sep 2022 |
| Series A | $3.50M | 1 |
|
03 Nov 2021 |
| Series A | $44.20M | 4 |
|
15 Jun 2021 |
We care about your data, and we'd love to use cookies make your experience better.
